Journal
BLOOD
Volume 131, Issue 16, Pages 1846-1857Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-09-805879
Keywords
-
Categories
Funding
- ERA-NET JCT (TRIAGE-MDS)
- HORIZON MDS-RIGHT
- Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development (Health and Labour Sciences Research Expenses for Commission)
- Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development (Applied Research for Innovative Treatment of Cancer)
- Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development (Project for Cancer Research and Therapeutic Evolution [P-CREATE])
- Japan Society for the Promotion of Science (JSPS) [26221308, 15H05909, 26890016]
- Grants-in-Aid for Scientific Research [26890016] Funding Source: KAKEN
Ask authors/readers for more resources
Therapy-related myeloid neoplasms (tMNs) are severe adverse events that can occur after treatment with autologous hematopoietic stem cell transplantation (ASCT). This study aimed to investigate the development of tMNs following ASCT at the molecular level by whole-exome sequencing (WES) and targeted deep sequencing (TDS) in sequential (pre-) tMN samples. WES identified a significantly higher number of mutations in tMNs as compared with de novo myelodysplastic syndrome (MDS) (median 27 vs 12 mutations; P = .001). The mutations found in tMNs did not carry a clear aging-signature, unlike the mutations found in de novo MDS, indicating a different mutational mechanism. In some patients, tMN mutations were identified in both myeloid and T cells, suggesting that tMNs may originate from early hematopoietic stem cells (HSCs). However, the mutational spectra of tMNs and the preceding malignancies did not overlap, excluding common ancestry for these malignancies. By use of TDS, tMN mutations were identified at low variant allele frequencies (VAFs) in transplant material in 70% of the patients with tMNs. Reconstruction of clonal patterns based on VAFs revealed that premalignant clones can be present more than 7 years preceding a tMN diagnosis, a finding that was confirmed by immunohistochemistry on bone marrow biopsies. Our results indicate that tMN development after ASCT originates in HSCs bearing (pre-) tMN mutations that are present years before disease onset and that post-ASCT treatment can influence the selection of these clones. Early detection of premalignant clones and monitoring of their evolutionary trajectory may help to predict the development of tMNs and guide early intervention in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available